Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

NCT02120456 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT02120456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02120456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Lead sponsor
LEO Pharma
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2014
Completion date
May 31, 2015
Enrollment
224 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis